Transgenic models of Huntington's disease

被引:49
|
作者
Sathasivam, K
Hobbs, C
Mangiarini, L
Mahal, A
Turmaine, M
Doherty, P
Davies, SW
Bates, GP
机构
[1] Kings Coll London, GKT Med & Dent Sch, Guys Hosp, London SE1 9RT, England
[2] Kings Coll London, Guys Hosp, GKT Med & Dent Sch, London SE1 9RT, England
[3] UCL, Dept Anat & Dev Biol, London WC1E 6BT, England
基金
英国惠康基金;
关键词
Huntington's disease; polyglutamine repeat; transgenic mouse; neurodegeneration; amyloid;
D O I
10.1098/rstb.1999.0447
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
1Huntington's disease (HD) is an inherited neurodegenerative disorder caused by a CAG-polyglutamine repeat expansion. A mouse model of this disease has been generated by the introduction of exon 1 of the human HD gene carrying highly expanded CAG repeats into the mouse germ line (R6 lines). Transgenic mice develop a progressive neurological phenotype with a movement disorder and weight loss similar to that in HD. We have previously identified neuronal inclusions in the brains of these mice that have subsequently been established as the pathological hallmark of polyglutamine disease. Inclusions are present before symptoms, which in turn occur long before any selective neuronal cell death can be identified. We have extended the search for inclusions to skeletal muscle, which, like brain, contains terminally differentiated cells. We have conducted an investigation into the skeletal muscle atrophy that occurs in the R6 lines, (i) to provide possible insights into the muscle bulk loss observed in HD patients, and (ii) to conduct a parallel analysis into the consequence of inclusion formation to that being performed in brain. The identification of inclusions in skeletal muscle might be additionally useful in monitoring the ability of drugs to prevent inclusion formation in vivo.
引用
收藏
页码:963 / 969
页数:7
相关论文
共 50 条
  • [1] Transgenic models of Huntington's disease
    Bates, GP
    Mangiarini, L
    Mahal, A
    Davies, SW
    [J]. HUMAN MOLECULAR GENETICS, 1997, 6 (10) : 1633 - 1637
  • [2] Transgenic Mouse Models of Parkinson's Disease and Huntington's Disease
    Skaper, Stephen D.
    Giusti, Pietro
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (04) : 455 - 470
  • [3] Transgenic mouse models for Huntington's disease.
    Reddy, PH
    Williams, M
    Miller, G
    Glass, M
    Paylor, R
    Garrett, L
    Herkenham, M
    Crawley, J
    Tagle, DA
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A52 - A52
  • [4] Experimental therapeutics in transgenic mouse models of Huntington's disease
    Beal, MF
    Ferrante, RJ
    [J]. NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) : 373 - 384
  • [5] Striatal neurochemical changes in transgenic models of Huntington's disease
    Ariano, MA
    Aronin, N
    Difiglia, M
    Tagle, DA
    Sibley, DR
    Leavitt, BR
    Hayden, MR
    Levine, MS
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 68 (06) : 716 - 729
  • [6] Experimental therapeutics in transgenic mouse models of Huntington's disease
    M. Flint Beal
    Robert J. Ferrante
    [J]. Nature Reviews Neuroscience, 2004, 5 : 373 - 384
  • [7] Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy
    Chang, Renbao
    Liu, Xudong
    Li, Shihua
    Li, Xiao-Jiang
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2179 - 2188
  • [9] Lipoic acid improves survival in transgenic mouse models of Huntington's disease
    Andreassen, OA
    Ferrante, RJ
    Dedeoglu, A
    Beal, MF
    [J]. NEUROREPORT, 2001, 12 (15) : 3371 - 3373
  • [10] Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease
    Andreassen, OA
    Ferrante, RJ
    Huang, HM
    Dedeoglu, A
    Park, L
    Ferrante, KL
    Kwon, J
    Borchelt, DR
    Ross, CA
    Gibson, GE
    Beal, MF
    [J]. ANNALS OF NEUROLOGY, 2001, 50 (01) : 112 - 117